Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old

NCT00439660 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

540

Enrollment

INDUSTRY

Sponsor class

Conditions

Diarrhea

Interventions

BIOLOGICAL: Oral Rotavirus Vaccine 116E Live Attenuated

Sponsor

Bharat Biotech International Limited

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]